Peptides in 2026: what changed
Peptides like BPC-157 went from gray-market products to something a licensed pharmacy may compound on a prescription, under an interim federal policy announced in late October 2026. It is not FDA approval, and it can be withdrawn.
What the interim policy covers
As reported, the U.S. Department of Health and Human Services announced on October 28, 2026 that it would not take enforcement action against licensed pharmacies that compound six peptides for individual patients with a prescription, subject to conditions: BPC-157, TB-500, Epitalon, Semax, KPV and MOTS-c. Reported conditions include sourcing from FDA-registered suppliers, a single active ingredient per product, specific routes of administration for each peptide, and a patient-specific prescription.
None of these peptides is FDA-approved. The FDA has not found them safe or effective for any use.
What a legitimate route looks like
- A licensed clinician evaluates you and writes a prescription.
- A licensed U.S. compounding pharmacy fills it for you by name.
- The label identifies it as a compounded drug.
- You have a clinician to contact about side effects.
What to avoid
- Products sold "for research use only" or "not for human consumption." They are not made or tested for people.
- Sellers that ship without a prescription.
- Peptides outside the six listed above, or any drug described as approved when it isn't.
Source: Meto, Oct. 29, 2026 (summary of the HHS announcement). We are confirming details against the Federal Register notice.